Controlling Inflammation to Treat Human Diseases

Press & Announcements

Date Description
February 1, 2008

Taligen Therapeutics Secures Series B Financing

September 10, 2007

• Dr. Holers and Taligen Collaborators present at International Complement Workshop

Dr. Michael Holers, Taligen’s CSO and Dr. Steve Tomlinson, a Taligen collaborator presented a total of 5 abstracts at the International Complement Workshop held in Cardiff, Wales, September 2007.

August 13, 2007

Taligen: De-amplifying complement (BioCentury; Emerging Company Profile, p11)

April 26, 2007

Dr. Emlen of Taligen to speak at the SMi Conference

Dr. Emlen of Taligen to speak at the SMi Conference on Asthma & COPD in London on Use of Complement-based Therapeutics in Asthma.

February 21, 2007

Taligen selected to present at Venture Capital of the Rockies

Dr. Woodruff Emlen will present an overview of Taligen at the VCiR conference 2/21/07

February 6, 2007

Taligen to Present at Biopartnering North America Conference, Vancouver, BC

Taligen has been selected as one of the emerging companies for presentation at the annual Biopartnering North America Conference.

December 4, 2006

Dr. Emlen, CEO of Taligen, to speak at CBI’s Airway Inflammation Drug Development Summit Conference

Dr. Emlen’s presentation entitled “A Novel Complement Inhibitor in the Treatment of Asthma” will give an overview of Taligen’s lead technology, TA106, and its development as a novel therapeutic for asthma.

October 25, 2006

Taligen collaborator presents at Eye Workshop in Argentina

Dr. Barbel Rohrer, in collaboration with Taligen, will present a paper entitled “Blocking alternative complement activation in an animal model of AMD” at the (MORE DETAILS TO FOLLOW)

October 23, 2006

Taligen Scientists to speak at International Complement Workshop in Beijing, China

Taligen’s co-founder, Dr. Michael Holers and Taligen-collaborators Drs. Tomlinson, Gilkeson and Thurman will present papers at the International Complement Workshop.

August 29, 2006

Taligen's TA106 Could Be Lucky Charm Vs. Asthma

August 1, 2006

Taligen Therapeutics Announces Successful Achievement of Series A Milestone

May 25, 2006

Dr. Emlen to speak at C21 conference

Taligen will present an overview of the Company and its Technology at the annual C21 conference in Monterrey, California on May 25.